An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021
-
摘要:
Ⅱ~Ⅳa期鼻咽癌主要治疗方式是放疗联合化疗。调强放射治疗时代，化疗的介入时机与具体实施仍存争议。以往有关鼻咽癌的临床指南对于具体的放疗技术、剂量分割以及放疗与化疗联合应用的具体方案通常阐述的比较笼统，并可能缺乏具体的实践指导性，2021年CSCO和ASCO鼻咽癌联合国际指南细致阐明了有关Ⅱ~Ⅳa期鼻咽癌根治性放化疗的模式与具体实施建议，本文旨在对该指南的具体细节进行解读。
Abstract:Radiotherapy combined with chemotherapy is the main treatment for stage Ⅱ-Ⅳa nasopharyngeal carcinoma (NPC). In the era of intensity-modulated radiation therapy, the timing and implementation of chemotherapy are still controversial. In the past, the clinical guidelines for NPC generally described the specific radiotherapy technology, dose fractionation and the specific scheme of combined application of radiotherapy and chemotherapy, and may lack specific practical guidance. The joint international guidelines for NPC by CSCO and ASCO elaborates the mode and specific implementation recommendations of radical chemoradiotherapy for stage Ⅱ-Ⅳa NPC. This article aims to interpret the specific details of the guideline.
-
Competing interests: The authors declare that they have no competing interests.作者贡献周亚娟、牟艳花：指南的学习与解读、资料收集及论文撰写胡德胜：参与指南的学习与解读、文章修改与补充
-
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2] Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage Ⅱ-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline[J]. J Clin Oncol, 2021, 39(7): 840-859. doi: 10.1200/JCO.20.03237
[3] Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional twodimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3): 286-293. doi: 10.1016/j.radonc.2012.08.013
[4] Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients[J]. J Clin Oncol, 2007, 25(31): 4873-4879. doi: 10.1200/JCO.2007.11.5501
[5] Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial[J]. Int J Radiat Oncol Biol Phys, 2006, 66(4): 981-991. doi: 10.1016/j.ijrobp.2006.06.013
[6] Luo MS, Huang GJ, Liu HB. Oncologic outcomes of IMRT versus CRT for nasopharyngeal carcinoma: Ameta-analysis[J]. Medicine (Baltimore), 2019, 98(24): e15951. doi: 10.1097/MD.0000000000015951
[7] Du T, Xiao J, Qiu Z, et al. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis[J]. PLoS One, 2019, 14(7): e0219611. doi: 10.1371/journal.pone.0219611
[8] Co J, Mejia MB, Dizon JM. Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature[J]. Head Neck, 2016, 38 suppl 1: E2130-E2142. http://europepmc.org/abstract/med/25546181
[9] Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase Ⅲ randomized Intergroup study 0099[J]. J Clin Oncol, 1998, 16(4): 1310-1317. doi: 10.1200/JCO.1998.16.4.1310
[10] Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase Ⅱ trial 0225[J]. J Clin Oncol, 2009, 27(22): 3684-3690. doi: 10.1200/JCO.2008.19.9109
[11] Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to inductionconcurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma[J]. Cancer, 2015, 121(8): 1328-1338. doi: 10.1002/cncr.29208
[12] Yang H, Chen X, Lin S, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial[J]. Radiother Oncol, 2018, 126(1): 37-42. doi: 10.1016/j.radonc.2017.07.020
[13] Ou X, Miao Y, Wang X, et al. The feasibility analysis of omission of elective irradiation to level IB lymph nodes in low-risk nasopharyngeal carcinoma based on the 2013 updated consensus guideline for neck nodal levels[J]. Radiat Oncol, 2017, 12(1): 137. doi: 10.1186/s13014-017-0869-x
[14] Zhang F, Cheng YK, Li WF, et al. Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: A retrospective analysis[J]. BMC Cancer, 2015, 15: 709. doi: 10.1186/s12885-015-1669-z
[15] Co JL, Mejia MBA, Dizon JMR. Evidence on effectiveness of upper neck irradiation versus whole neck irradiation as elective neck irradiation in node-negative nasopharyngeal cancer: A meta-analysis[J]. J Glob Oncol, 2018, 4: 1-11.
[16] Li JG, Yuan X, Zhang LL, et al. A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with nodenegative nasopharyngeal carcinoma[J]. Cancer, 2013, 119(17): 3170-3176. doi: 10.1002/cncr.28201
[17] Gao Y, Zhu G, Lu J, et al. Is elective irradiation to the lower neck necessary for N0 nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2010, 77(5): 1397-1402. doi: 10.1016/j.ijrobp.2009.06.062
[18] Tang LL, Tang XR, Li WF, et al. The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement[J]. Oral Oncol, 2017, 69: 68-73. doi: 10.1016/j.oraloncology.2017.03.010
[19] Xiao F, Dou S, Li Y, et al. Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes[J]. Clin Transl Oncol, 2019, 21(6): 781-789. doi: 10.1007/s12094-018-1988-z
[20] Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma: Phase Ⅲ randomized trial[J]. J Natl Cancer Inst, 2011, 103(23): 1761-1770. doi: 10.1093/jnci/djr432
[21] Wang S, Li S, Shen L. Combined chemoradiation vs radiation therapy alone in stage-Ⅱ nasopharyngeal carcinoma: A meta-analysis of the published literature[J]. Curr Probl Cancer, 2018, 42(3): 302-318. doi: 10.1016/j.currproblcancer.2018.03.004
[22] Liu F, Jin T, Liu L, et al. The role of concurrent chemotherapy for stageⅡ nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis[J]. PLoS One, 2018, 13(3): e0194733. doi: 10.1371/journal.pone.0194733
[23] Xu C, Zhang LH, Chen YP, et al. Chemoradiotherapy versus radiotherapy alone in stageⅡ nasopharyngeal carcinoma: A systemic review and meta-analysis of 2138 patients[J]. J Cancer, 2017, 8(2): 287-297. doi: 10.7150/jca.17317
[24] Huang X, Chen X, Zhao C, et al. Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stageⅡ nasopharyngeal carcinoma: A phase 2 multicenter clinical trial[J]. Front Oncol, 2020, 10: 1314. doi: 10.3389/fonc.2020.01314
[25] Tang C, Wu F, Wang R, et al. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phaseⅡ clinical trial[J]. Am J Cancer Res, 2016, 6(9): 2064-2075. http://europepmc.org/articles/PMC5043115/?report=classic
[26] Wu X, Huang PY, Peng PJ, et al. Long-term follow-up of a phase Ⅲ study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma[J]. Ann Oncol, 2013, 24(8): 2131-2136. doi: 10.1093/annonc/mdt163
[27] Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis[J]. Lancet Oncol, 2015, 16(6): 645-655. doi: 10.1016/S1470-2045(15)70126-9
[28] Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial[J]. Eur J Cancer, 2017, 75: 150-158. doi: 10.1016/j.ejca.2017.01.002
[29] Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: A randomized controlled trial[J]. J Clin Oncol, 2018, 31: 3091-3100. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiAzYzUzYjY2NzQ5MDFmNzk5MDIwOTQ1NjA4OGM1NTliYxoIcDFhang0OGo%3D
[30] Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2015, 91(5): 952-960. doi: 10.1016/j.ijrobp.2015.01.002
[31] Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phaseⅡ study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation[J]. Ann Oncol, 2012, 23(2): 427-435. doi: 10.1093/annonc/mdr116
[32] Hui EP, Ma BB, Leung SF, et al. Randomized phaseⅡ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J]. J Clin Oncol, 2009, 27(2): 242-249. doi: 10.1200/JCO.2008.18.1545
[33] Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial[J]. Int J Cancer, 2019, 145(1): 295-305. doi: 10.1002/ijc.32099
[34] Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial[J]. Lancet Oncol, 2016, 17(11): 1509-1520. doi: 10.1016/S1470-2045(16)30410-7
[35] Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase Ⅲ multicentre randomised controlled trial[J]. Eur J Cancer, 2019, 119: 87-96. doi: 10.1016/j.ejca.2019.07.007
[36] Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase Ⅲ multicentre randomised controlled trial[J]. Eur J Cancer, 2017, 75: 14-23. doi: 10.1016/j.ejca.2016.12.039
[37] Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med, 2019, 381(12): 1124-1135. doi: 10.1056/NEJMoa1905287
[38] Tan TH, Soon YY, Cheo T, et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis[J]. Radiother Oncol, 2018, 129(1): 10-17. doi: 10.1016/j.radonc.2018.02.027
[39] Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)[J]. Ann Oncol, 2018, 29(3): 731-736. doi: 10.1093/annonc/mdx770
[40] Lee JY, Sun JM, Oh DR, et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phaseⅡ trial (KCSG-HN10-02)[J]. Radiother Oncol, 2016, 118(2): 244-250. doi: 10.1016/j.radonc.2015.11.030
[41] Liang H, Li WX, Lv X, et al. Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979)[J]. J Clin Oncol, 2017, 35: 6006. doi: 10.1200/JCO.2017.35.15_suppl.6006
[42] Ng WT, Tung SY, Lee V, et al. Concurrent-adjuvant chemoradiation therapy for stage Ⅲ-ⅣB nasopharyngeal carcinoma-exploration for achieving optimal 10-year therapeutic ratio[J]. Int J Radiat Oncol Biol Phys, 2018, 101(5): 1078-1086. doi: 10.1016/j.ijrobp.2018.04.069
[43] Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 trials[J]. Eur J Cancer, 2011, 47(5): 656-666. doi: 10.1016/j.ejca.2010.10.026
[44] Peng H, Chen L, Zhang Y, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a prospective phase Ⅲ clinical trial[J]. Oncologist, 2016, 21(11): 1369-1376. doi: 10.1634/theoncologist.2016-0105
[45] Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: Individual patient data pooled analysis of four randomized trials[J]. Clin Cancer Res, 2018, 24(8): 1824-1833. doi: 10.1158/1078-0432.CCR-17-2656
[46] Petit C, Lee AWM, Carmel A, et al. Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8, 221 patients[J]. J Clin Oncol, 2020, 38: 6523. doi: 10.1200/JCO.2020.38.15_suppl.6523
[47] Lee AWM, Ngan RKC, Ng WT, et al. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma[J]. Cancer, 2020, 126(16): 3674-3688. doi: 10.1002/cncr.32972
[48] Lee AWM, Tung SY, Ng WT, et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity[J]. Cancer, 2017, 123(21): 4147-4157. doi: 10.1002/cncr.30850
[49] Chen Y, Sun Y, Liang SB, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage Ⅲ to IVB nasopharyngeal carcinoma from endemic regions of China[J]. Cancer, 2013, 119(12): 2230-2238. doi: 10.1002/cncr.28049
[50] Lee AW, Tung SY, Chan AT, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2011, 98(1): 15-22. doi: 10.1016/j.radonc.2010.09.023
[51] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. doi: 10.1016/S0140-6736(19)30956-0
[52] Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial[J]. Lancet Oncol, 2012, 13(2): 163-171. doi: 10.1016/S1470-2045(11)70320-5
[53] Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage Ⅲ and Ⅳ nasopharyngeal cancer of the endemic variety[J]. J Clin Oncol, 2005, 23(27): 6730-6738. doi: 10.1200/JCO.2005.16.790
[54] Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trial[J]. Eur J Cancer, 2007, 43(9): 1399-1406. doi: 10.1016/j.ejca.2007.03.022
[55] Chitapanarux I, Kittichest R, Tungkasamit T, et al. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/ fluorouracil in nasopharyngeal cancer: A multicenter randomized trial[J]. Curr Probl Cancer, 2021, 45(1): 100620. doi: 10.1016/j.currproblcancer.2020.100620
[56] Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid[J]. Int J Radiat Oncol Biol Phys, 2014, 89(1): 21-29. doi: 10.1016/j.ijrobp.2014.01.052
[57] Liu YC, Wang WY, Twu CW, et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients[J]. Oral Oncol, 2017, 64: 15-21. doi: 10.1016/j.oraloncology.2016.11.008
[58] Chen JH, Huang WY, Ho CL, et al. Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage Ⅳ nasopharyngeal carcinoma[J]. Head Neck, 2019, 41(11): 3775-3782. doi: 10.1002/hed.25904
[59] Wang WY, Lin TY, Twu CW, et al. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA[J]. Oncotarget, 2016, 7(27): 42608-42616. http://europepmc.org/articles/PMC5173160/
[60] Wu Y, Wei XY, Yuan ZL, et al. Phase Ⅱ study of induction chemotherapy followed by concurrent chemoradiotherapy with raltitrexed and cisplatin in locally advanced nasopharyngeal carcinoma[J]. Chin J Cancer Res, 2020, 32(5): 665-672.
[61] Lee AW, Ng WT, Pan JJ, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma[J]. Radiother Oncol, 2018, 126(1): 25-36. doi: 10.1016/j.radonc.2017.10.032
[62] 中国临床肿瘤学会《CSCO鼻咽癌诊疗指南》[M]. 北京: 人民卫生出版社, 2020: 20-34. Chinese society of Clinical Oncology《CSCO guidelines for diagnosis and treatment of nasopharyngeal carcinoma》[M]. Beijing: People's Medical Publishing House, 2020: 20-34.
-
期刊类型引用(3)
1. 李发龙, 孟祥凯, 王忠利, 秦静, 王思钰, 李玉锋, 刘娣. 2023年山东省莒县户籍居民主要恶性肿瘤死亡及减寿分析. 现代医院. 2025(06) 
百度学术
2. 黄芸，陈文俊，朱伟敏，王峰. 2015—2022年克拉玛依市消化系统恶性肿瘤死亡特征与灰色模型预测分析. 疾病预防控制通报. 2024(05): 42-46+56 . 百度学术
3. 王红英，李胜，明娟，李洁，李元林，杨勇攀，宋启瑞. 2006—2020年中国居民胃癌死亡趋势分析——基于年龄-时期-出生队列模型. 卫生经济研究. 2023(11): 43-48 . 百度学术
其他类型引用(0)
下载:
计量
- 文章访问数: 3018
- HTML全文浏览量: 728
- PDF下载量: 1426
- 被引次数: 3
